eligibility_summary
Eligible: 3–75 yrs with relapsed/refractory AML per 2017 China criteria (incl post‑HSCT/extramedullary), lacking effective options or choosing NKG2D CAR‑NK, ECOG 0–2, ≥12‑week life expectancy, adequate cardiac, hepatic, renal function, negative HIV/HBV/HCV/syphilis. Exclude: APL, major organ/CV/CNS disease, coagulopathy, serious infection, immune/autoimmune disease or severe allergy, recent trials/therapy/surgery, active HIV/HBV/HCV/syphilis, pregnancy/lactation, investigator decision.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: NKG2D CAR-NK cells (gene-engineered natural killer cell therapy). Patients receive lymphodepleting chemotherapy followed by infusion of NK cells engineered to express a chimeric antigen receptor based on the activating receptor NKG2D. Mechanism: the CAR targets stress-inducible NKG2D ligands (e.g., MICA, MICB, ULBP family) commonly expressed on AML blasts, ligand binding triggers NK activation signaling (e.g., DAP10/CD3z costimulation), leading to perforin/granzyme-mediated cytotoxicity and cytokine release against leukemic cells. Targets: AML blasts and potentially leukemic stem/progenitor cells expressing NKG2D ligands. Pathways: NKG2D–ligand axis and innate immune cytotoxic pathways. Design: single-arm, dose-escalation to determine MTD in relapsed/refractory AML.